Affiliation:
1. Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China
2. Department of Cardiology, Shaanxi Academy of Traditional Chinese Medicine, Xi’an 710005, China
Abstract
Anthracyclines represent a highly efficacious class of chemotherapeutic agents employed extensively in antitumor therapy. They are universally recognized for their potency in treating diverse malignancies, encompassing breast cancer, gastrointestinal tumors, and lymphomas. Nevertheless, the accumulation of anthracyclines within the body can lead to significant cardiac toxicity, adversely impacting both the survival rates and quality of life for tumor patients. This limitation somewhat restricts their clinical utilization. Determining how to monitor and mitigate their cardiotoxicity at an early stage has become an urgent clinical problem to be solved. Therefore, this paper reviews the mechanism of action, early monitoring, and strategies for the prevention of anthracycline-induced cardiotoxicity for clinical reference.
Funder
China Academy of Chinese Medical Sciences and Technology Innovation Project
National Natural Science Foundation of China
Capability Enhancement Project of Xiyuan Hospital, China Academy of Chinese Medical Sciences
Chinese Academy of Chinese Medical Sciences